Yeji

$NBIX

NEUROCRINE BIOSCIENCES INC

Runway:cash-flow +
NasdaqMarket cap: —CIK 0000914475

Upcoming catalysts

2 surfaced
FDA approvalDate TBD
$NBIXNEUROCRINE BIOSCIENCES INC
crenessity
“CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH).”
FDA approvalDate TBD
$NBIXNEUROCRINE BIOSCIENCES INC
crenessity
“CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia.”

Drug pipeline

ingrezza
crenessity
ingrezza sprinkle
Valbenazine
Schizophrenia
NBI-1065845
Major Depressive Disorder
Indiplon
Insomnia
NBI-6024
Type 1 Diabetes Mellitus
TAK-653
Healthy Volunteers
NBI-1065890
Tardive Dyskinesia
NBI-98854 50 mg capsule
Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
TAK-831 Oral Tablet
Healthy Volunteers
NBI-5788
Multiple Sclerosis
TAK-653 Placebo
Depressive Disorder
VY-AADC02
Parkinson's Disease
Crinecerfont
Congenital Adrenal Hyperplasia
NBI-827104
Essential Tremor
NBI-98854 50 mg capsule once daily
Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects
NBI-74788
CAH - Congenital Adrenal Hyperplasia
interleukin-4 PE38KDEL cytotoxin
Breast Cancer
NBI-77860
Congenital Adrenal Hyperplasia
Placebo
Anhedonia
NBI-98854
Tourette Syndrome
Opicapone
Parkinson Disease
VY-AADC01
Idiopathic Parkinson's Disease
Luvadaxistat
Schizophrenia
NBI-1117570
Schizophrenia
Amphetamine
Healthy Volunteers
NBI-1117568
Schizophrenia
NBI-1070770
Major Depressive Disorder
TAK-041
Stable Schizophrenia
TAK-831 Tablet T2
Healthy
TAK-831 Oral Suspension
Schizophrenia, Cerebellar Ataxia
NBI-34060
Insomnia
NBI-921352
SCN8A Developmental and Epileptic Encephalopathy Syndrome
TAK-831
Healthy Volunteers
TAK-831 T2
Healthy Volunteers

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT07114874NBI-1117568Phase 3Recruiting2031-12-01
NCT07187375CrinecerfontPhase 2Recruiting2029-09-06
NCT07227818NBI-1117568Phase 3Recruiting2029-07-01
NCT06966401NBI-1065845Phase 3Recruiting2029-05-01
NCT07196501NBI-1065845Phase 3Recruiting2028-07-01
NCT07536269CrinecerfontPhase 2Not Yet Recruiting2028-03-01
NCT07288320NBI-1117568Phase 2Recruiting2028-02-01
NCT07105098NBI-1117568Phase 3Recruiting2027-11-01
NCT06963034NBI-1117568Phase 3Recruiting2027-10-01
NCT07288333NBI-1117570Phase 2Recruiting2027-08-01
NCT06963021NBI-1065845Phase 3Recruiting2027-07-01
NCT06786624NBI-1065845Phase 3Recruiting2027-07-01
NCT06911112NBI-1065845Phase 3Recruiting2027-07-01
NCT07365462NBI-1065890Phase 2Recruiting2027-02-01
NCT07105111ValbenazinePhase 4Recruiting2027-01-01
NCT06312189ValbenazinePhase 3Enrolling By Invitation2026-04-01
NCT04400331ValbenazinePhase 3Active Not Recruiting2026-03-01
NCT05226780NBI-921352Phase 2Terminated2025-11-12
NCT05206513PlaceboPhase 3Completed2025-10-16
NCT06267846NBI-1070770Phase 2Completed2025-07-25

Recent catalysts

FDA approvalDec 13, 2024· 540d ago· success
$NBIXNEUROCRINE BIOSCIENCES INC
crenessity
“openFDA ORIG (TYPE 1) approval of CRENESSITY — application NDA218808”
FDA approvalApr 30, 2024· 767d ago· success
$NBIXNEUROCRINE BIOSCIENCES INC
ingrezza sprinkle
“openFDA ORIG (TYPE 3) approval of INGREZZA SPRINKLE — application NDA218390”
FDA approvalAug 18, 2023· 1023d ago· success
$NBIXNEUROCRINE BIOSCIENCES INC
ingrezza
“openFDA SUPPL (EFFICACY) approval of INGREZZA — application NDA209241”